Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.

@article{Grossi2010FutureSF,
  title={Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.},
  author={Francesco Grossi and Kaoru Kubota and Federico Cappuzzo and F. De Marinis and Cesare Gridelli and Marianna Aita and Jean-yves Douillard},
  journal={The oncologist},
  year={2010},
  volume={15 10},
  pages={1102-12}
}
Despite recent progress in the development of new molecularly targeted agents, the chemotherapy regimens considered standard at the end of the last century--that is, two-drug combinations consisting of either cisplatin or carboplatin plus a third-generation agent (docetaxel, paclitaxel, gemcitabine, or vinorelbine)--remain the primary treatment option for advanced non-small cell lung cancer (NSCLC) patients. Most recently, the existing standard of care has been amended to reflect the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…